文献速递系统性红斑狼疮

狼疮关节炎与肌肉骨骼疾病活动度(LAMDA)工具的推导、验证与阈值提议:一项队列研究

Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study.
PubMed 文献 · Lancet Rheumatol · 2026-09-02

本研究基于USEFUL前瞻性纵向多中心队列的133例接受肌注糖皮质激素治疗的SLE患者,推导出以超声滑膜炎为锚定的LAMDA复合活动度评分,该评分保留66关节肿胀计数、ESR、医生肌肉骨骼疾病活动度VAS和患者肌肉骨骼疼痛VAS四个变量。

要点

  • LAMDA评分由66关节肿胀计数、ESR、医生VAS和患者疼痛VAS构成,可替代66关节为28关节肿胀计数。
  • 外部队列中LAMDA提议阈值在区分治疗意图和患者可接受症状状态上优于单纯肿胀关节计数。

核心结论

  • LAMDA是一种源自超声的临床疾病活动度测量工具,有望改善临床试验和真实世界中狼疮关节炎的评估。

研究设计与样本

  • 研究为队列研究,从英格兰七家医院招募的USEFUL前瞻性纵向多中心研究中纳入133例因狼疮关节炎接受肌注糖皮质激素治疗的SLE患者进行推导。
  • 外部队列从Leeds Teaching Hospitals NHS Trust招募44例参与者,由未参与USEFUL研究的临床医生收集临床结局和治疗意图。

主要发现

  • LAMDA模型保留四个变量:66关节肿胀计数、ESR、医生肌肉骨骼疾病活动度VAS和患者肌肉骨骼疼痛VAS。

关键数值与推荐

  • LAMDA提议的阈值包括试验入组、最小疾病活动度、患者可接受症状状态和最小临床重要改善,均通过ROC曲线分析建立。
  • 外部队列中LAMDA提议阈值在区分治疗意图和患者可接受症状状态方面优于单纯肿胀关节计数。

临床怎么用

  • LAMDA可用于临床试验和真实世界实践中评估狼疮关节炎疾病活动度,并可采用28关节肿胀计数替代66关节计数以提高可行性。

局限性

  • 研究未报告LAMDA提议阈值的确切数值。
  • 研究未报告外部队列中LAMDA与具体结局指标相关的具体数值。
  • 研究未报告外部验证中区分治疗意图和患者可接受症状状态的具体统计量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcome measures for lupus arthritis that are not sensitive to change might contribute to misleading results in systemic lupus erythematosus (SLE) trials. We aimed to optimise lupus arthritis assessment by developing a novel composite disease activity measure, derived against ultrasound synovitis and incorporating participant-reported outcomes. METHODS: In this cohort study we derived the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) score from baseline data in a prospective, longitudinal, multicentre study (USEFUL) of participants with SLE receiving intramuscular glucocorticoid therapy for lupus arthritis recruited from seven hospitals in England. Penalised multiple quantile (median) regression of total combined grey scale and power Doppler scores from bilateral hand and wrist joint ultrasounds on inflammatory arthritis core set variables defined by the American College of Rheumatology (tender joint count in 68 joints, swollen joint count in 66 joints, Health Assessment Questionnaire Disability Index, erythrocyte sedimentation rate [ESR], and visual analogue scales [VAS] for patient's musculoskeletal pain and disease activity and physician's musculoskeletal disease activity), and early morning stiffness severity VAS was used to derive the score. We assessed convergent construct validity, known groups validity, and responsiveness. We established thresholds of meaning for trial entry, minimal disease activity, participant acceptable symptom state, and minimal clinically important improvement using receiver operating characteristic curve analysis. A separate external validation cohort was recruited from Leeds Teaching Hospitals NHS Trust, clinical outcomes and treatment intention were collected by clinicians who were not involved in the USEFUL study. The construct validity of LAMDA within this external validation cohort was assessed, including discrimination of treatment intention and participant acceptable symptom state. People with lived experience of SLE were involved in the design and delivery of both the USEFUL study and the present study. FINDINGS: 133 participants recruited between Oct 20, 2016, and Dec 20, 2018, were included from the USEFUL study; mean age was 47·0 years (IQR 35·0-55·0), 126 (95%) were female, seven (5%) were male, and 82 (62%) were White. The model retained four variables in the LAMDA score: swollen joint count in 66 joints, ESR, VAS for physician musculoskeletal disease activity, and participant musculoskeletal pain. High intraclass correlation (>0·99) supported directly substituting swollen joint count in 28 joints for swollen joint count in 66 joints to improve feasibility. LAMDA showed good construct validity, correlating with conventional disease activity measures, ultrasound findings, and patient-reported outcomes. LAMDA was responsive, yielding a medium-to-large early treatment effect following glucocorticoid therapy (effect size 0·40, p<0·0001). Provisional thresholds of meaning showed good logical consistency with participant characteristics and patient-reported change in musculoskeletal pain. The external validation cohort included 44 participants, recruited between Nov 15, 2017, and July 23, 2020; median age was 48·5 years (IQR 39·0-56·0), 38 (86%) were female, six (14%) were male, and 32 (73%) were White. The findings from the external validation cohort were supportive of the initial findings. LAMDA was correlated with multiple participant reported outcome measures and the proposed thresholds of meaning outperformed swollen joint counts alone in discriminating treatment intention and participant acceptable symptom state. INTERPRETATION: LAMDA is a novel ultrasound-derived clinical disease activity measure that should improve the assessment of lupus arthritis in clinical trials and real-world practice. Further validation is underway in large multinational randomised controlled trials. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wood S, Mahmoud K, Conaghan PG, et al. Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study. Lancet Rheumatol. 2026. PMID: 42685740. doi:10.1016/S2665-9913(26)00208-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。